Physician profile
Carol A Eke
NPI 1023598885
$3,238.96
in general payments reported to CMS, 2019-2025
24 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.58 · 2022: $96.19 · 2023: $915 · 2024: $1,137 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,087.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $633.98 | 2023-2025 | Epclusa, Descovy, Vemlidy |
| Viiv Healthcare Company | $367.20 | 2024-2025 | Apretude, Dovato |
| Genzyme Corporation | $240.54 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $130.94 | 2025 | Voquezna |
| Novo Nordisk INC | $124.98 | 2024 | |
| Verona Pharma, INC. | $124.58 | 2025 | Ohtuvayre |
| Corium, LLC | $124.19 | 2023 | Azstarys |
| Xeris Pharmaceuticals, INC. | $122.33 | 2024 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $121.82 | 2025 | Shingrix |
| Abbvie INC. | $117.31 | 2024 | |
| Merck Sharp & Dohme LLC | $109.60 | 2024 | Capvaxive |
| Edwards Lifesciences Corporation | $100.92 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Alexion Pharmaceuticals, INC. | $98.44 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $96.19 | 2025 | |
| Idorsia Pharmaceuticals US INC | $96.19 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $93.53 | 2023 | Yupelri |
| Pfizer INC. | $93.35 | 2025 | |
| Alkermes, INC. | $84.01 | 2024 | Lybalvi |
| Cmp Pharma, INC. | $72.69 | 2023-2025 | Carospir, Norliqva, Tadliq |
| Theratechnologies INC. | $70.34 | 2023 | Trogarzo |
| Biogen, INC. | $68.61 | 2023 | |
| Smith+Nephew, INC. | $55.58 | 2021 | |
| Coloplast Corp | $53.82 | 2023 | Titan, Altis |
| Medtronic, INC. | $37.82 | 2023 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Eke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.